capecitabine + camrelizumab

Capecitabine + camrelizumab is an investigational combination therapy consisting of capecitabine, an oral prodrug of 5-fluorouracil (5-FU), and camrelizumab, a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1). Capecitabine is metabolized to 5-FU in vivo, which inhibits thymidylate synthase and disrupts DNA and RNA synthesis in tumor cells, leading to cytotoxicity. Camrelizumab blocks PD-1 on T cells, preventing its interaction with PD-L1/PD-L2 ligands on tumor or immune cells; this reactivates T-cell mediated antitumor immunity. The combination aims to enhance antitumor efficacy by pairing direct cytotoxic chemotherapy with immune checkpoint inhibition. This regimen has been studied in various solid tumors including metastatic gastrointestinal cancers and triple-negative breast cancer[2][5][9].

Other names

camrelizumab + capecitabine